trending Market Intelligence /marketintelligence/en/news-insights/trending/oIL9x0Qn6ZVW6-23P8ErRw2 content esgSubNav
In This List

Imagion Biosystems reduces staff by one-third to preserve working capital

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Imagion Biosystems reduces staff by one-third to preserve working capital

Imagion Biosystems Ltd. said it reduced its staff by one-third in a restructuring to preserve its working capital.

The Melbourne, Australia-based healthcare equipment developer said the restructuring will allow it to better align resources with expenditures as the company advances into the clinic working with collaborators and partners.

While the reduction in headcount will reduce its rate of cashburn, Imagion is not expecting to generate significant operating revenues in the next few years, the company said in a news release.

Imagion added that the continuation of its operations hinges on equity and non-dilutive funding sources. Pursuant to this, the company plans to raise capital during the present quarter.

The company develops the MagSense System and Test to detect breast cancer with a certain mutation of human genes. The cancer diagnostic device received breakthrough designation from the U.S. Food and Drug Administration in July.